Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection
Public ClinicalTrials.gov record NCT01132313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II)
Study identification
- NCT ID
- NCT01132313
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 488 participants
Conditions and interventions
Conditions
Interventions
- BI 207127 Drug
- BI 201335 Drug
- Ribavirin Drug
- BI 207217 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Sep 30, 2014
- Completion
- Sep 30, 2014
- Last update posted
- Jan 31, 2016
2010 – 2014
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1241.21.0003 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 1241.21.0006 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1241.21.0004 Boehringer Ingelheim Investigational Site | San Francisco | California | — | — |
| 1241.21.0011 Boehringer Ingelheim Investigational Site | Palm Harbor | Florida | — | — |
| 1241.21.0013 Boehringer Ingelheim Investigational Site | Valparaiso | Indiana | — | — |
| 1241.21.0008 Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| 1241.21.0019 Boehringer Ingelheim Investigational Site | Fayetteville | North Carolina | — | — |
| 1241.21.0012 Boehringer Ingelheim Investigational Site | Arlington | Texas | — | — |
| 1241.21.0005 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1241.21.0007 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1241.21.0010 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1241.21.0017 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01132313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 31, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01132313 live on ClinicalTrials.gov.